



2543-1-039

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jonathan Alexander Terrett EXAMINER: Aeder, Sean
SERIAL NO : 10/510,507 ART UNIT: 1642
FILED : April 20, 2005
FOR : DIAGNOSIS OF CARCINOMA USING RAIG1 POLYPEPTIDES

DECLARATION UNDER 37 C.F.R. 1.132

Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 October 3, 2006

Lois A. Snure
Name of Person Depositing Mail)

Lois A. Snure 10/3/06
(Signature and Date)

I, ALASDAIR CRAIG STAMPS as evidenced by my signature below, declare the following:

1. I am a Molecular Biologist, having received my Ph.D. degree in 1988
After that, I served as a postdoctoral fellow at the Royal Free Hospital London, and after that at the Institute of Cancer Research, Royal Marsden Hospital, London. I am currently employed as a Senior Scientist at UCB Celltech, Slough, Berks, UK.
2. My curriculum vitae is attached hereto as Exhibit A.
3. My principal area of research is therapeutic target discovery in human cancer.
4. I am not the inventor of subject matter claimed in the above-referenced patent application.


5. **Immunohistochemical Analysis of RAIG1 expression in cancer tissue.**

The immunohistochemical data presented with this Declaration shows that increased staining was seen in human colon cancer tissue sections incubated with anti-RAIG1 antibody, compared to adjacent sections to which the negative control antibody was applied. This data, which correlates with RAIG1 mRNA quantification data, indicates that an anti-RAIG1 antibody could be used to target RAIG1 in colon tumours and deliver a therapy, whether via antibody coupled toxin, induction of immune effectors or modulation of RAIG1 function, or any combination of these.

6. All statements made herein of my own knowledge are true and all statements made on information and belief are believed to be true; and further these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application, or any patent issuing thereon.

Submitted by

ALASDAIR STAMPS

A handwritten signature in black ink, appearing to read 'Alasdair Stamps', written over a horizontal line.

Date Signed: 28/09, 2006



CURRICULUM VITAE

Alasdair Stamps
33 Bowyer Road
Abingdon
OXON
OX14 2EW

PROFILE

Molecular biologist with 20 years' experience in therapeutic target discovery in oncology and inflammatory disease.

PROFESSIONAL EXPERIENCE

1998 -2006 UCB – Celltech and Oxford Glycosciences

Positions held: Principal Scientist, Head of Gene Informatics, Head of Target Validation and Discovery

1995 - 1998 Yamanouchi Research Institute, Oxford

Position held: Senior Scientist

**1990 - 1995 Institute of Cancer Research, Royal Marsden
Hospital/Ludwig Institute for Cancer Research**

Position held: Postdoctoral Fellowship

1988 - 1990 Royal Free Hospital School of Medicine

Position held: Postdoctoral Fellowship

OTHER RELEVANT EXPERIENCE

Oxfordshire Bioinformatics Forum Steering Group Member
Oxfordshire Bioscience Network Advisor

EDUCATION & QUALIFICATIONS

**1981 - 1984 University of Aberdeen
BSc Biochemistry (Hons) 2.1**

**1984 - 1987 Beatson Institute for Cancer Research, Glasgow
PhD
"Transcriptional analysis of bovine papillomavirus type 4"**

PUBLICATIONS

Adam PJ, Terrett JA, Steers G, Stockwin L, Loader JA, Fletcher GC, Lu LS, Leach BI, Mason S, Stamps AC, Boyd RS, Pezzella F, Gatter KC, Harris AL.

CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. *Br J Cancer* 2006 Aug 7;95(3):298-306.

Haworth A, Stamps A, Bateson L

Oxfordshire Bioscience Cluster Report 2005

http://www.oxfordshirebioscience.com/seeb/images/publications/oxford_biotech_cluster.pdf

Stamps AC, Terrett JA.

Pharmacoproteomics. In Hall, Pirmohamed & Tucker (eds.) Pharmacogenetics, Marcel Dekker 2004.

Stamps AC, Adam P, Terrett JA.

Proteomics and Cancer. *Applied Genomics and Proteomics* 2004.

McGowan SJ, Terrett JA, Brown C, et al.

Annotation of the Human Genome by High-Throughput Sequence Analysis of Naturally Occurring Proteins. *Current Proteomics* 2004 Jan;1:41-8.

<http://www.bentham.org/1-1/cp1-1/Andrew%20Llyall.pdf>

Stamps AC, Adam PJ, Terrett JA.

A practical route to target discovery via proteomics. *Biosystems Solutions* 2003

Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P, De Belin J, Steers G, Pezzella F, Sachsenmeier KF, Stamps AC, Herath A, Sim E, O'Hare MJ, Harris AL, Terrett JA.

Arylamine N-acetyltransferase-1 (NAT-1) Is Highly Expressed in Breast Cancers and Conveys Enhanced Growth and Resistance to Etoposide in Vitro. *Molecular Cancer Research* 2003 Sept 1;1(11).

Boyd RS, Adam PJ, Patel S, Loader JA, Berry J, Redpath NT, Poyser HR, Fletcher GC, Burgess NA, Stamps AC, Hudson L, Smith P, Griffiths M, Willis TG, Karran EL, Oscier DG, Catovsky D, Terrett JA, Dyer MJ.

Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B. *Leukemia*. 2003 Aug;17(8):1605-12.

McKenzie E, Young K, Hircock M, Bennett J, Bhaman M, Felix R, Turner P, Stamps A, McMillan D, Saville G, Ng S, Mason S, Snell D, Schofield D, Gong H, Townsend R, Gallagher J, Page M, Parekh R, Stubberfield C.

Biochemical characterisation of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. *Biochem J*. 2003 Jul 15;373(Pt 2):423-35.

- Stamps AC, Terrett JA, Adam PJ.
Application of in situ RT-PCR to tissue microarrays. *J Nanobiotechnology* 2003 1:3
- Adam P, Boyd R, Tyson K, Fletcher G, Stamps A, Hudson L, Poyser H, Redpath N, Griffiths M, Steers G, Harris A, Patel S, Berry J, Loader J, Townsend RR, Daviet L, Legrain P, Parekh R, Terrett JA.
Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. *J Biol Chem*. 2003 Feb 21;278(8):6482-9.
- Patel S, Turner PR, Stubberfield C, Barry E, Rohlf CR, Stamps A, Tyson K, Terrett J, Box G, Eccles S, Page MJ.
Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer. *Int J Cancer*. 2002 Feb 1;974:416-24.
- McKenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R, Hircock M, Patel S, Barry E, Stubberfield C, Terrett J, Page M.
Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. *Biochem Biophys Res Commun*. 2000 Oct 5;2763:1170-7.
- Stamps A, Elmore MA, Hill ME, Makda AA, Kelly K, Finnen MJ.
Mammalian lyso phosphatidic acyltransferases. *Research Disclosures*. 1997 400; 551-553. GenBank Accession numbers AF011374 and AF015811
- Stamps A, Elmore MA, Hill ME, Kelly K, Makda AA, Finnen MJ.
A human cDNA sequence with homology to non-mammalian lyso phosphatidic acid acyltransferases. *Biochem J*. 1997 326; 455-461. GenBank Accession number U75971
- Makda AA, Elmore MA, Hill ME, Stamps A, Tejura S, Finnen MJ.
Cell type distribution and subcellular location of enzymes involved in the metabolism of acyl ethanolamines. *Prostaglandins, Leukotrienes and Essential Fatty Acids*. 1997 57; 264.
- Makda AA, Elmore MA, Hill ME, Stamps A, Tejura S, Finnen MJ.
Differential effects of CB1 and CB2 agonists on cAMP levels and MAP kinase activation in human peripheral blood mononuclear cells. *Biochem Soc Trans*. 1997 25; 217S.
- Makda AA, Elmore MA, Hill ME, Stamps A, Tejura S, Finnen MJ.
Differential effects of CB1 and CB2 agonists on cAMP levels and MAP kinase activation in human peripheral blood mononuclear cells. *Immunology*. 1996 89; S1, N131.
- Birdsall SH, Stamps AC, Gusterson BA, Shipley JM, Gill SE, Cooper CS.
No rearrangement of the CHOP and TLS/FUS genes in two cases of phyllodes tumor of the breast. *Cancer Genet Cytogenet*. 1996 87; 90-91.
- Stamps AC, Davies SC, Burman J, O'Hare MJ.
Analysis of proviral integration in human mammary epithelial cell lines immortalised using retroviral infection with a ts SV40 T-antigen construct. *Int J Cancer*. 1994 57; 865-874.

Eeles RA, Warren W, Stamps A.
The PCR revolution. In: Yarnold J., Stratton M., McMillan T. (eds): Molecular Biology for Oncologists. 1993 *Elsevier Science Publishers B.V., The Netherlands*.

Eeles RA, Stamps A.
Polymerase Chain Reaction PCR: The technique and its applications. 1993 *R. G. Landes Company, Austin, Texas*.

Stamps AC, Davies S, O'Hare MJ.
The tumour suppressor gene status of conditionally immortalised human mammary epithelial cell lines. *The Breast* 1992 1; 153.

Stamps AC, Gusterson BA, O'Hare MJ.
Are tumours immortal? *Eur J Cancer* 1992 28A; 1495-1500.

Eeles RA, Warren W, Stamps A.
The PCR revolution. *Eur J Cancer* 1992 28; 289-293.

Gusterson BA, Anbazhagan R, Warren W, Midgely C, Lane DP, O'Hare M, Stamps A, Carter R, Jayatilake H.
Expression of p53 in premalignant and malignant squamous epithelium. *Oncogene* 1991 6; 1785-1789.

Harrison TJ, Lin Y, Stamps A, Dusheiko G, Zuckerman AJ.
Hepatitis B virus-associated hepatocellular carcinoma in African patients. *Cancer Detection & Prevention* 1990 14; 457-460.

Stamps AC, Campo MS.
Mapping of two novel transcripts of bovine papillomavirus type 4. *J gen Virol*. 1988 69; 3033-3045.

RECENT CONFERENCE PRESENTATIONS

From High-Throughput Proteomics to Therapeutic Antibodies: Accelerating the Discovery Process.

Presented at Cambridge Health Institute's Beyond Genome 2002 Conference, San Diego, June 19th 2002

Proteomics and the Selection of Oncology Kinase Targets

Presented at SMI's Kinases Conference, London, April 10th 2003

Informatic Needs of the Bioscience Industry

Presented at ICT Networks/OxIT Cluster Conference & Exhibition, Oxford, March 25th 2004

Biologics & the Technology Revolution

Presented at Oxfordshire Bioscience Network's Business for Bioscience Course, Oxford, April 1st 2004